Table 1 Characteristics of included studies.

From: Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials

StudyYearIndicationLength of treatmentTotal CBD dose/dayaType of CBDFood directionsNumber of participantsAge inclusion criteriaMean ageMale (%)Clobazam co-prescription (%)Valproate co-prescription (%)
Consroe et al. [26]1991Huntington’s Disease6 weeksb10 mg/kgNot specifiedEmpty stomach with a glass of water1847.861.100
GWP Fatty Liver Disease NCT01284634 [3]2014Fatty Liver Disease8 weeks200/400/800 mgPlant derived (GWP42003)Fasted, 30 min before meal2518+46.448
Jadoon et al. [2]2016Type II Diabetes13 weeks200 mgPlant derived (GWP42003)Fasted, 30 min before meal2718+57.763
Naftali et al. [25]c2017Crohn’s Disease8 weeks20 mg sublingualPlant derived1918–753957.9
Devinsky et al. (GWPCARE1) [18]2017Dravet Syndrome11 days titration and 12 weeks maintenance treatment up to 10 days taper period or OLE20 mg/kgGWP42003-P, plant derived1202–189.8526559
Boggs et al. [19]2018Schizophrenia6 weeks600 mgProvided by STI Pharmaceuticals4118–6547.469.4?d
McGuire et al. [4]2018Schizophrenia6 weeks1000 mgPlant derived (GWP42003)8818–6540.858
GWP Clobazam Interaction Study NCT02565108 [20]2018Clobazam10 days titration and 21 days maintenance treatment 10 day taper period or OLE20 mg/kgPlant derived (GWP42003-P)2018–6536.850100
Devinsky et al. (GWPCARE1 – Dose Ranging) [21]2018Dravet Syndrome3, 7 or 11 days titration 21 days maintenance treatment 10 days taper period or OLE5/10/20 mg/kgPlant derived (GWP42003-P)344–107.6476865
Devinsky et al. (GWPCARE3) [17]2018Lennox-Gastaut Syndrome7 or 11 days titration 12 weeks maintenance treatment 10 days taper period or OLE10/20 mg/kgPlant derived (GWP42003-P)2252–5515.657.34938
Thiele et al. (GWPCARE4) [22]2018Lennox-Gastaut Syndrome11 days titration 12 weeks maintenance treatment 10 days taper period or OLE20 mg/kgPlant derived (GWP42003-P)1712–5515.451.54940
Taylor et al. [23]2018Healthy Adults1 week1.5 g or 3 g per day (half dose on day 7)Plant derived (GWP42003)2418–452633.3
Hill et al. NCT03102918 [24]2019Cannabis Use Disorder6 weeks800 mgPlant derived (GWP42003)1018–6530.84000
  1. OLE open-label extension.
  2. aOral dosing unless stated otherwise.
  3. bCrossover study with a 1 week washout and second 6 weeks treatment period, only pre-crossover data were extracted.
  4. cNaftali 2017 met all inclusion criteria but did not contribute data to meta-analysis.
  5. d25% of participants were prescribed a mood stabilizer which may include valproate.